Healthcare entity
funding is the sole category represented across all 1 tracked stories. BV100 is most often covered alongside AMR Action Fund, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. BV100 is most often covered alongside AMR Action Fund, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.8 for that window. BV100 appears in 1 tracked Healthcare story from March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BV100. Shared-story counts are live from our verified record — not editorial picks.
BioVersys AG reported its full-year 2025 financial results, highlighting significant clinical progress for its lead antimicrobial candidates and a stable cash position. The Swiss biotech successfully advanced its AlpE program into Phase 2b trials, reinforcing its leadership in the fight against multi-drug resistant infections.
Source: manilatimes.net · finanznachrichten.de
BV100 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
